Although cardiac glycosides (CGs) are not specifically used for the treatment of viral infections (Buckalew, 2015), some studies have shown their antiviral effects on different respiratory viruses and associated this effect with the inhibition of Na+/K+-ATPase (NKA) (Sato and Muro, 1974). This evidence concerns the gene TAC1 and viral infectious disease.